Abstract:<h3>Purpose/Objective(s)</h3> 5-fluorouracil -based regimens are the mainstay treatment for colorectal cancer. However, the limited response rate to 5-fluorouracil -based regimens hampered the increase in the treatment efficacy of locally advanced rectal cancer. During the drug screening in the rectal cancer organoid biobank (n=124), we found out that more than half of the organoids that were resistant to 5-fluorouracil monotherapy and sensitive to irinotecan maintained sensitive status to the treatment of 5-fluorouracil combined with irinotecan (combination-sensitive), while a quite proportion of them turn to become remarkably resistant to 5-fluorouracil plus irinotecan (combination-resistant). Some studies suggested the mechanism of 5-fluorouracil -based resistance was associated with the activation of some oncogenic pathways. However, the mechanism of the addition of 5-fluorouracil promoting the resistance to irinotecan is still unclear. <h3>Materials/Methods</h3> To investigate the relationship between the combination-resistant organoids and corresponding patient responses, we collected patient clinical responses and survival outcomes. RNA sequencing and ATAC sequencing were performed to identify differential genes and their enrichment pathways. Moreover, small molecule inhibitors were used to try to reverse the resistance induced by 5-fluorouracil. <h3>Results</h3> Twenty-one organoids showed sensitivity to irinotecan and resistance to 5-fluorouracil. Among them, 8 organoids (38.1%) were combination-resistant and 13 organoids (61.9%) showed sensitivity to combination treatment. Combination-resistant organoids corresponding patients had worse pathologic tumor regression grades (pTRGs) distribution (8/8, 100% had TRGs of 2-3 versus 100% had TRGs of 0-1 in combination-sensitive patients; p< 0.05) and disease-free survival (DFS) rates (HR:11.57, 95% IC:1.025-130.5; p=0.0047) than patients whose organoids were combination-sensitive. Combination-resistant organoids had higher expression of Ki-67 and CD44 and reduced cleaved-caspase 3 in the combination treatment group and 5-fluorouracil group compared with the irinotecan group and control. Furthermore, we identified hedgehog pathway activation after adding 5-fluorouracil to irinotecan in combination-resistant organoids through RNA sequencing and ATAC sequencing. GANT-61, an inhibitor of the hedgehog pathway, increased sensitivity to the combination of 5-fluorouracil and irinotecan in combination-resistant organoids. <h3>Conclusion</h3> We found that organoids which are sensitive to irinotecan turn to become resistant to 5-fluorouracil combined with irinotecan. Moreover, corresponding patients had worse responses and a lower DFS rate. The hedgehog pathway is activated in these organoids after the addition of 5-fluorouracil to irinotecan, and GANT-61 could reverse the resistance caused by 5-fluorouracil. However, more organoid-associated trials with large-scale patients are warranted to reverse the 5-fluorouracil-based resistance in the future.

Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress

THE SYNERGISTIC ANTI-PROLIFERATIVE EFFECT OF CURCUMIN AND FLUOROURACIL ON HUMAN COLON CANCER CELL LINE HT-29

Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells

Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.

Effects of Different Chemotherapeutic Agents on Reversing the Acquired Resistance to TRAIL Gene in DLD1 Colon Cancer Cells

Effects of curcumin on 5-fluorouracil resistance of colon cancer cells through the PI3K/AKT/mTOR pathway via MACC1

Curcumin Reverses Chemoresistance of Human Gastric Cancer Cells by Downregulating the NF-κB Transcription Factor

Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level

Curcumin Regulates ERCC1 Expression and Enhances Oxaliplatin Sensitivity in Resistant Colorectal Cancer Cells Through Its Effects on Mir-409-3p

Curcumin Prevents Induced Drug Resistance: A Novel Function?

Curcumin inhibits tumor epithelial-mesenchymal transition by downregulating the Wnt signaling pathway and upregulating NKD2 expression in colon cancer cells

GDF15 Repression Contributes to 5-Fluorouracil Resistance in Human Colon Cancer by Regulating Epithelial-Mesenchymal Transition and Apoptosis

In Vitro Additive Antitumor Effects of Dimethoxycurcumin and 5‐fluorouracil in Colon Cancer Cells

Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway

Curcumin inhibits colorectal cancer development by blocking the YAP/TAZ signaling axis

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Curcumin suppresses colorectal cancer by induction of ferroptosis via regulation of p53 and solute carrier family 7 member 11/glutathione/glutathione peroxidase 4 signaling axis

Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer

Targeting Thymidylate Synthase and tRNA-Derived Non-Coding RNAs Improves Therapeutic Sensitivity in Colorectal Cancer

5-Fluorouracil Promotes the Resistance of Patient-Derived Rectal Cancer Organoids to Irinotecan via Activating the Hedgehog Pathway

Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1